Skip to content
Open access

Cardiometabolic index and central adiposity as non-invasive markers of hepatic steatosis and elevated liver stiffness in chronic hepatitis B

2026 · Hepatology Forum · Vol 7, pp. 319-328 · 0 citations · 27 references

TL;DR

Whether the cardiometabolic in-dex (CMI), modified CMI (MCMI), modified CMI (MCMI) and simple anthropometry are associated with hepatic steatosis and elevated liver stiffness is assessed.

Abstract

Background and Aim: Residual liver disease in chronic hepatitis B (CHB) under long-term antiviral therapy is increasingly metabolic. We assessed whether the cardiometabolic in-dex (CMI), modified CMI (MCMI) and simple anthropometry are associated with hepatic steatosis and elevated liver stiffness. Materials and Methods: In a two-part cross-sectional study, CMI and MCMI were com-pared between inactive hepatitis B virus carriers (n=21) and matched controls (n=27). Separately, 92 nucleos(t)ide-treated CHB patients underwent vibration-controlled tran-sient elastography (VCTE). Significant steatosis was a controlled attenuation parameter (CAP) ≥268 dB/m and elevated liver stiffness a liver stiffness measurement ≥7.0 kPa. No biopsy was performed. Areas under the curve (AUC) were compared by the DeLong test, and cutoff performance was internally validated by bootstrap. Results: CMI and MCMI did not differ between carriers and controls (p>0.6). Significant steatosis occurred in 44 of 91 (48%) and elevated liver stiffness in 48 of 90 (53%). CMI correlated with CAP (rho=0.37, p

Read PDF

Similar papers

Oct 2026

Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance.

In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin res...

Eddison Godinez Leiva, Diana Barb, S. Kalavalapalli et al. · 0 citations
Open access 2026

Cardiometabolic index fails to discriminate the histological status of metabolic dysfunction-associated steatotic liver disease patients: A report from biopsy-proven Turkish metabolic dysfunction-associated steatotic liver disease cohort

Background and Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge, and cardiovascular mortality has been shown to be significantly associated with the cardiometabolic index (CMI). However, data linking CMI with histological severity in MASLD are lacking. In this stu...

Saima Fakih, Kaya Eda, A. Kırık et al. · 0 citations
Open access Oct 2026

Genetic and Body Composition Factors Associated with Metabolic-Associated Steatotic Liver Disease: A Cross-Sectional Analysis of a Health Screening Cohort

Introduction Metabolic-associated steatotic liver disease (MASLD), newly defined in 2023, is characterized by excessive hepatic triglyceride accumulation in the presence of cardiometabolic risk factors. The body roundness index (BRI), an indicator of body fat distribution and visceral adiposity, has been proposed as a...

Yi-Hsuan Shen, Yi-Chen Lee, Tzu-Jung Chou et al. · 0 citations
Open access Oct 2026

The role of non-invasive markers of hepatic steatosis in detecting epicardial obesity

Aim . To evaluate the diagnostic value of various non-invasive methods for assessing hepatic steatosis as potential markers of epicardial obesity (EO) in individuals without cardiovascular disease. Material and methods . This cross-sectional study included 303 patients without cardiovascular diseases with a me...

A. Bragina, Y. Rodionova, A. V. Podzolkov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.